| Literature DB >> 32814587 |
Christel Gill Haanshuus1, Kristine Mørch2,3.
Abstract
BACKGROUND: PCR can be positive weeks after effective malaria treatment, potentially leading to over diagnose of recrudescence and re-infections. The DNA detected by PCR post-treatment might stem from residuals of destroyed asexual parasites, or from live gametocytes. The objective of this clinical observational study was to describe the presence of positive PCR for Plasmodium falciparum and Plasmodium vivax in follow-up samples post-treatment from returned travellers, and the proportion of positive PCR due to gametocytes.Entities:
Keywords: DNA; Gametocyte; Malaria; PCR; Plasmodium falciparum; Plasmodium vivax; Post-treatment; RT-PCR; Travellers; mRNA
Mesh:
Substances:
Year: 2020 PMID: 32814587 PMCID: PMC7436973 DOI: 10.1186/s12936-020-03367-6
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Plasmodium DNA and gametocyte-specific mRNA detections among malaria patients after treatment (N = 13)
| Patient | Species | No days since treatment | Microscopy (parasite %) | Genus DNA | No copies/rxn | Genus 18S mRNA PCR (Ct) | Pfs25/Pvs25 mRNA PCR (Ct) | No. copies/rxn | |
|---|---|---|---|---|---|---|---|---|---|
| No. 1 | 0 | Pos (2) | Pos (24) | 1.1 × 103 | Pos (26) | ||||
| 1 | Pos (1) | Pos (25) | 4.3 × 102 | Pos (28) | Pos (17) | Pos (29) | 3.2 × 103 | ||
| No. 2 | 0 | Pos (4) | Pos (18) | 5.7 × 105 | Pos (19) | ||||
| 1 | Pos (4) | Pos (21) | 7.0 × 105 | Pos (22) | Pos (12) | Pos (34) | 95 | ||
| No. 3 | 0 | Pos (12) | |||||||
| 1 | Neg | Pos (22) | 3.7 × 104 | Pos (26) | |||||
| 2 | Neg | Pos (23) | 1.5 × 104 | Pos (29) | |||||
| 11 | Neg | Pos (30) | 200 | Pos (35) | Pos (25) | Neg | |||
| No. 4 | 0 | Pos (< 1)* | |||||||
| 31 | Neg | Neg | Neg | Neg | |||||
| No. 5 | 0 | Pos (< 1) | |||||||
| 32 | Neg | Pos (37) | 2 | Neg | Neg | ||||
| No. 6 | 0 | Pos (2) | Pos (19) | 3.9 × 105 | Pos (20) | ||||
| 1 | Pos (< 0.5) | Pos (24) | 7.7 × 103 | Pos (27) | Pos (17) | Pos (31) | 420 | ||
| 37 | Neg | Pos (39) | 1 | Neg | Neg | ||||
| No. 7 | 0 | Pos (10) | Pos (15) | 4.0 × 106 | Pos (16) | ||||
| 4 | Neg | Pos (25) | 6.3 × 103 | Pos (29) | Pos (23) | Neg | |||
| 11 | Neg | Pos (29) | 400 | Pos (35) | Pos (24) | Neg | |||
| 39 | Neg | Neg | Neg | Neg | Neg | ||||
| No. 8 | 0 | Pos (30) | Pos (16) | 1.8 × 106 | Pos (18) | ||||
| 1 | Pos (6) | Pos (16) | 3.0 × 106 | Pos (17) | Pos (7) | Pos (29) | 2.2 × 103 | ||
| 45 | Neg | Pos (34) | 16 | Neg | Neg | Neg | |||
| No. 9 | 0 | Pos (6)* | |||||||
| 49 | Neg | Pos (34) | 11 | Pos (36) | Neg | Neg | |||
| No.10 | 0 | Pos (0.5) | |||||||
| 2 | Pos* | Pos (7) | Pos (17) | 9.6 × 106 | |||||
| No. 11 | 0 | Pos (0.5)a | |||||||
| 6 | Neg | Pos (39) | 1 | Neg | Neg | ||||
| No. 12 | 0 | Pos | Pos (22) | 4.8 × 104 | |||||
| 23 | Neg | Neg | Neg | Neg | |||||
| No. 13 | 0 | Pos | |||||||
| 54 | Neg | Neg | Neg | Neg | Neg |
rxn reaction
aGametocytes seen by microscopy
PCR results associated with microscopy findings and clinical characteristics
| Patient | Species | No. days since treatment | Microscopy (parasite%) | PCR | Fever duration before treatment (days) | Treatment | Origin/years out of endemic area | Comorbidity |
|---|---|---|---|---|---|---|---|---|
| No. 1 | 0 | Pos (2) | Pos | 35 | AL | SSA/1 | HIV | |
| 1 | Pos (1) | Posb,c | ||||||
| No. 2 | 0 | Pos (4) | Pos | 2 | A, AL | SSA/8 | HIV | |
| 1 | Pos (4) | Posb,c | ||||||
| No. 3 | 0 | Pos (12) | 3 | A, AP | Norway | |||
| 1 | Neg | Pos | ||||||
| 2 | Neg | Pos | ||||||
| 11 | Neg | Posb | ||||||
| No. 4 | 0 | Pos (< 1)a | 38 | AP | SSA/10 | |||
| 31 | Neg | Neg | ||||||
| No. 5 | 0 | Pos (< 1) | 7 | AL | SSA/46 | |||
| 32 | Neg | Pos | ||||||
| No. 6 | 0 | Pos (2) | Pos | 9 | Q, A, AL | SSA/21 | ||
| 1 | Pos (< 0.5) | Posb,c | ||||||
| 37 | Neg | Pos | ||||||
| No. 7 | 0 | Pos (10) | Pos | 21 | A, AL | SSA/10 | HIV | |
| 4 | Neg | Pos | ||||||
| 11 | Neg | Pos | ||||||
| 39 | Neg | Neg | ||||||
| No. 8 | 0 | Pos (30) | Pos | 3 | A, | Norway | ||
| 1 | Pos (6) | Posb,c | Erythrocyte | |||||
| 45 | Neg | Pos | apheresis, AL | |||||
| No. 9 | 0 | Pos (6)a | 13 | A, AP, AL | SSA/17 | Sickle cell disease | ||
| 49 | Neg | Pos | ||||||
| No.10 | 0 | Pos (0.5) | 10 | AP, P | SEA/30 | |||
| 2 | Posa | Posb,c | ||||||
| No. 11 | 0 | Pos (0.5)a | Not known | AP, P | SSA | |||
| 6 | Neg | Pos | ||||||
| No. 12 | 0 | Pos | Pos | 2 | A, AP, P | Norway | ||
| 23 | Neg | Neg | ||||||
| No. 13 | 0 | Pos | 6 | C, P | Norway | |||
| 54 | Neg | Neg |
AL artemether-lumefantrine, A artesunate IV (intravenous), PA atovaquone-proguanil, Q quinine IV, C chloroquine, P primaquine, HIV human immunodeficiency virus, SSA sub-Saharan Africa, SEA Southeast Asia
aGametocytes seen by microscopy
bDetection of 18S mRNA transcripts (Produced by all parasite stages)
cDetection of gametocyte-specific mRNA